Clinical Trial Update: An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients with Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas [NA]

View source ↗

Summary

This clinical trial update shows that the NCT06759740 study evaluating 68Ga-DOTA-SEMA for preoperative imaging of GLP1R-positive insulinomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Insulinoma

Drugs mentioned

• 68Ga-DOTA-SEMA (68Ga-DOTA-SEMA)

Snippet

Sponsor: The Affiliated Hospital Of Southwest Medical University | Conditions: Hypoglycaemia | NA | Status: WITHDRAWN